Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mitochondrial diseases
Biotech
Pharming pays $66M for Abliva, mitochondrial disease med
Pharming is paying $66.1 million to acquire the Swedish biotech Abliva and its phase 2-stage med for a type of mitochondrial disease.
James Waldron
Dec 16, 2024 4:39am
AbbVie continues Parkinson's pursuit with $110M Mitokinin buy
Oct 5, 2023 10:30am
'Elegant' study connects COVID with mitochondria gene disruption
Aug 10, 2023 10:30am
Mayo Clinic cell and gene therapy accelerator launches startup
Jan 3, 2023 9:50am
Khondrion forges on despite phase 2 mitochondrial disease fail
Nov 22, 2022 4:50am
Tour de biotech: Cyclerion peddles through another disease area
Oct 6, 2022 10:30am
